What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Chemotherapy, Acute lymphocytic leukemia, Surgery and Oncology are his primary areas of study.
His research on Internal medicine often connects related topics like Gastroenterology.
Günter Henze combines subjects such as Clinical trial, Pediatrics and Lymphoblastic lymphoma with his study of Chemotherapy.
His study in Clinical trial is interdisciplinary in nature, drawing from both Hematology, Prospective cohort study and Multicenter trial.
His Acute lymphocytic leukemia research includes elements of Childhood Acute Lymphoblastic Leukemia, Incidence, Retrospective cohort study and Acute leukemia.
His research integrates issues of Hematopoietic stem cell transplantation and Minimal residual disease in his study of Oncology.
His most cited work include:
- Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90 (581 citations)
- Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 (464 citations)
- Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 (416 citations)
What are the main themes of his work throughout his whole career to date?
Günter Henze spends much of his time researching Internal medicine, Chemotherapy, Acute lymphocytic leukemia, Oncology and Surgery.
Günter Henze studied Internal medicine and Gastroenterology that intersect with Adverse effect and Toxicity.
Günter Henze usually deals with Chemotherapy and limits it to topics linked to Methotrexate and Prednisone.
His study in Acute lymphocytic leukemia is interdisciplinary in nature, drawing from both Hematology, El Niño, Survival analysis and Chromosomal translocation.
The various areas that Günter Henze examines in his Oncology study include Prospective cohort study, Immunophenotyping, Incidence and Lymphoblastic Leukemia.
Surgery is closely attributed to Clinical trial in his research.
He most often published in these fields:
- Internal medicine (48.00%)
- Chemotherapy (26.57%)
- Acute lymphocytic leukemia (25.71%)
What were the highlights of his more recent work (between 2008-2020)?
- Internal medicine (48.00%)
- Oncology (24.57%)
- Chemotherapy (26.57%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Oncology, Chemotherapy, Transplantation and Surgery.
His Internal medicine study focuses mostly on Childhood Acute Lymphoblastic Leukemia, Minimal residual disease, Lymphoblastic Leukemia, Acute lymphocytic leukemia and Hematology.
As part of one scientific family, Günter Henze deals mainly with the area of Oncology, narrowing it down to issues related to the Bone marrow, and often Disease and B cell.
Günter Henze focuses mostly in the field of Chemotherapy, narrowing it down to matters related to Proportional hazards model and, in some cases, First relapse.
His studies in Transplantation integrate themes in fields like Retrospective analysis, Imatinib, Imatinib mesylate, Stem cell and Clofarabine.
His research in Surgery intersects with topics in Gastroenterology and Cohort.
Between 2008 and 2020, his most popular works were:
- Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000 (359 citations)
- Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008 (270 citations)
- Prognostic Value of Minimal Residual Disease Quantification Before Allogeneic Stem-Cell Transplantation in Relapsed Childhood Acute Lymphoblastic Leukemia: The ALL-REZ BFM Study Group (261 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Günter Henze mainly investigates Internal medicine, Oncology, Chemotherapy, Surgery and Transplantation.
His study in Internal medicine concentrates on Minimal residual disease, Induction chemotherapy, Hematopoietic stem cell transplantation, Leukemia and Acute lymphocytic leukemia.
His studies deal with areas such as Gene rearrangement, Clinical trial, Karyotype, Trisomy and Maintenance therapy as well as Acute lymphocytic leukemia.
While the research belongs to areas of Oncology, Günter Henze spends his time largely on the problem of Immunology, intersecting his research to questions surrounding Stem cell and Neoplasm.
The concepts of his Chemotherapy study are interwoven with issues in Medulloblastoma and Proportional hazards model.
His Surgery study combines topics in areas such as Cancer and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
